Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase 3 trial for the treatment of immune thrombocytopenia (ITP) in pediatric patients. Avatrombopag is a thrombopoietin receptor agonist (TPO-RA). Its phase 3 study – AVA-PED-301 will assess the efficacy, safety, and pharmacokinetics in the treatment of the […]